KZA kazia therapeutics limited

Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity, page-5

  1. 1,195 Posts.
    lightbulb Created with Sketch. 937
    LabMan 4/11/22, 09:18 PM
    It is know that TAM is associated with poor prognosis in most cancers. Established also is that PI3K TAM kinase inhibition, can stimulate antitumour immunity, enhance chemo sensitivity and diminish metastatic potential, essentially what is sought of such a drug in this study. The direct association here with GDC 0084 from MD Anderson and MGH for the first time, to essentially reduce the presence of TAM in the tumor micro environment, is high signifiance.

    Initial interim data from paxalisib phase II brain metastases study with Alliance for Clinical Trials in Oncology 1H CY2022.
    IMO, Dr Priscilla K. Brastianos selected paxalisib, ahead of the other FDA approved PI3K inhibitors for the Alliance trial, due to paxalisib's drug safety, efficacy and ability to cross the blood brain barrier.

    Regards.


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.